Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• Direct to Consumer Wearables For Children: Who, What, When and How?
  Miniaturization of electronics and sensors has led to increased direct to consumer wearable (D2CW) technologies initially designed for wellness assessment and fitness tracking.
• To Bridge or Not to Bridge in the Periprocedural Setting: Cangrelor Versus Glycoprotein IIb/IIa Inhibitors
  Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 inhibitor such as clopidogrel, ticagrelor, or prasugrel is recommended post percutaneous coronary intervention (PCI) for 6-12 months, depending on stent type and patient-specific factors.
• Randomized Comparison of Efficacy and Safety of Lipid Lowering With Statin Monotherapy Versus Statin-Ezetimibe Combination for High-Risk Cardiovascular Disease
  The goal of the RACING trial was to compare the clinical efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients at very high risk for cardiovascular diseases.
• Tirzepatide Once Weekly for the Treatment of Obesity
  The goal of the SURMOUNT-1 trial was to assess the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist versus placebo in overweight or obese adults without diabetes.
• GDMT and Risk of Death With Primary Prevention ICDs
  For patients with heart failure with reduced ejection fraction (HFrEF) and a primary prevention implantable cardioverter-defibrillator (ICD), what is the impact of number of HFrEF guideline-directed medical therapy (GDMT) medications on all-cause mortality?